MedTrace Logo

Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial

NCT04445935 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-06-24

No results posted yet for this study

Summary

Patients with COVID-19 associated ARDS and mechanical ventilation have a high mortality. Part of the disease is an activation of the coagulation system which seems to contribute to clotformation in the pulmonary bloodstream. Recently we implemented an algorithm applying higher doses of heparins (LMWH). However, this approach could not inhibit clotformation enough. Bivalirudin could prevent clotformation better and support dissolving existing clots.

Therefore, we want to compare 50 patients with the standard treatment with 50 patients under bivalirudin treatment which we normally apply in patients with a HIT-syndrome.

Our primary outcome measure is oxygenation reflected as P/F ratio.

Conditions

  • Anticoagulation in COVID-19 ARDS

Interventions

DRUG

Bivalirudin Injection

The patients will receive iv Bivalirudin according to the institutional HIT protocol.

DRUG

Standard treatment

This group will receive standard anticoagulation with LMWH/UFH

Sponsors & Collaborators

  • Hamad Medical Corporation

    lead INDUSTRY

Principal Investigators

  • Marcus Lance, MD, PhD · HMC

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-28
Primary Completion
2020-09-28
Completion
2021-03-28

Countries

  • Qatar

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04445935 on ClinicalTrials.gov